CRISPR Therapeutics AG: ORBIS INVESTMENT MANAGEMENT LTD amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Orbis Investment Management amended its Schedule 13G filing on CRISPR Therapeutics AG, disclosing a change in its passive stake in the gene-editing company. The filing, submitted to the SEC under accession number 0000940594-26-000069, updates the asset manager's previously reported position. Schedule 13G amendments are typically filed when a passive investor's ownership crosses or adjusts relative to the 5% threshold, though the headline did not specify the exact stake size or direction of the change. The disclosure matters because it signals shifting institutional positioning in CRISPR Therapeutics, a closely watched gene-editing stock. Investors will watch for the detailed filing to confirm Orbis's exact ownership percentage and whether the adjustment reflects a build or trim of the position.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
ORBIS INVESTMENT MANAGEMENT LTD, CRISPR Therapeutics AG